TOP GUIDELINES OF TRACLEER

six The phosphodiesterase-five inhibitor sildenafil is accredited for PAH in FC I–IV from the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which include bosentan, sitaxentan and ambrisentan are oral therapies licensed to be used in PAH. As no oral agent has demonstrated superiority there continues to